Skip to main content

Tekmira Closes $30M Stock Offering

Premium

Tekmira Pharmaceuticals this week announced that it has completed the public offering of $30 million of its common stock.

Through the transaction, Tekmira sold 3.75 million shares at $8 apiece. The underwriters of the offering have a 30-day option to purchase an additional 15 percent of the shares to cover over-allotments.

Tekmira stock was selling for around $8.68 during midday trading on Wednesday.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.